Newsletters

[Experimental & Molecular Medicine] Investigators developed a CAR-like signal-switching receptor-macrophage that recognizes IL-10, a major immunosuppressive cytokine enriched in solid tumors, and converts this inhibitory signal into a pro-inflammatory activation through the Toll-like receptor 9 (TLR9) intracellular signaling pathway.

[Stand Up To Cancer] Stand Up To Cancer® as announced that Caitlin Zebley of St. Jude Children’s Research Hospital, is the recipient of the 2026 SU2C Maverick Early Career Scientist Award. The funding from the 2026 Maverick Award will support Dr. Zebley’s ongoing research focused on developing effective CAR T-cell therapies for children with acute myelogenous leukemia (AML).

[Signal Transduction and Targeted Therapy] The authors highlight how CAR-based strategies can be adapted across diverse disease settings by redirecting engineered immune responses toward disease-sustaining cellular compartments.

[Cancer Gene Therapy] Scientists investigated the therapeutic potential of nicotinamide mononucleotide, a metabolic modulator known to enhance immune cell functionality, in augmenting mesothelin CAR-NK cell efficacy against ovarian cancer.

[Nature Biotechnology] Investigators presented a virus-like particle-based toolkit that delivers diverse CRISPR editing modalities to human monocytes, macrophages and dendritic cells with high efficiency while preserving viability and innate immune responsiveness.

[Cancer Immunology Research] To uncover determinants of therapeutic efficacy, scientists analyzed the infusion products of eight relapsed/refractory diffuse large B-cell lymphoma patients with distinct clinical responses to axicabtagene ciloleucel using single-cell transcriptomics.

[Advanced Drug Delivery Reviews] Scientists highlight key challenges related to the biodistribution, activation, and persistence of modified T cells, with an emphasis on the potential of these strategies for treating not only blood cancers but also solid tumors, autoimmune diseases, and beyond.

[Molecular Cancer Therapeutics] Researchers developed and preclinically validated a novel CAR-T therapy targeting Integrin αvβ6 for aggressive pancreatic ductal adenocarcinoma and lung adenocarcinoma.

[TMU] Congratulations to Dr. April Khademi who was awarded $100K in funding from Breast Cancer Canada (BCC) in partnership with AstraZeneca Canada. At Dr. Khademi’s Toronto Metropolitan University (TMU) Image Analysis in Medicine Lab, her team is developing AI-based tools to accurately predict a patient’s risk and likely response to different treatments.

[American Cancer Society] The American Cancer Society announced a new $5.45 million commitment from the Lisa Dean Moseley Foundation. Among the partnership's most significant achievements is the American Cancer Society-Lisa Dean Moseley Foundation Cancer Stem Cell Consortium.

[Advanced Science] Investigators identify Toll-interacting protein (TOLLIP) as a critical regulator of psoriasis pathogenesis through its modulation of glycolytic metabolism.

[Science Advances] Researchers explored how extra-genetic factors, particularly metabolic and oxidative stress, influence Darier disease, showing that impaired antioxidant defenses can compromise SERCA2 function and weaken epidermal cell adhesion.